Overall, the data for the use of conventional as well as lifestyle-based CV treatments to prevent cardiotoxicity in breast cancer patients prescribed anthracyclines and/or HER2-targeted therapies is promising. This evidence concerns the gene ERBB2 and breast carcinoma.